🇺🇸 FDA
Patent

US 8513005

DNA immunogenic composition comprising a full-length modified poxvirus L1R gene fused to a tPA leader sequence

granted A61KA61K2039/53A61K39/12

Quick answer

US patent 8513005 (DNA immunogenic composition comprising a full-length modified poxvirus L1R gene fused to a tPA leader sequence) held by The United States of America as represented by the Secretary of the Army expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Army
Grant date
Tue Aug 20 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/53, A61K39/12, A61K39/285, A61P